United BioSource Corporation, Dorval, Quebec, Canada.
Prostate Cancer Prostatic Dis. 2010 Sep;13(3):278-84. doi: 10.1038/pcan.2010.5. Epub 2010 Mar 9.
Limited data are available concerning long-term prostate cancer (PCa)-related medical costs for use in assessing PCa prevention strategies. The aim of this study was to examine treatment, long-term survival, and long-term PCa-related costs by cancer stage. Costs in phases of care based on the natural history of PCa were also examined. Our data illustrate that initial care is characteristic of a rapid rate of cost accrual. This rate then decreases during continuing care. For terminal care, only stage IV resumes a rate of cost accrual similar to initial care. With average PCa-related costs of $18,168 observed over an average follow-up of 4 years, prevention strategies may result in a reduction in medical costs.
关于前列腺癌（PCa）相关医疗费用的长期数据有限，这些数据可用于评估 PCa 预防策略。本研究的目的是根据癌症分期来检查治疗、长期生存和长期 PCa 相关成本。还检查了基于 PCa 自然史的护理阶段的成本。我们的数据表明，初始护理的特点是成本快速累积。然后，在持续护理期间，这一速度下降。对于终末期护理，只有第四阶段的成本累积速度恢复到类似于初始护理的水平。在平均 4 年的随访中，观察到平均与 PCa 相关的成本为 18168 美元，预防策略可能会降低医疗成本。
Zotero 插件